190 related articles for article (PubMed ID: 38804470)
21. The history and pharmacology of buprenorphine: New advances in cats.
Clark TP
J Vet Pharmacol Ther; 2022 Jul; 45 Suppl 1():S1-S30. PubMed ID: 35790013
[TBL] [Abstract][Full Text] [Related]
22. Advances in the delivery of buprenorphine for opioid dependence.
Rosenthal RN; Goradia VV
Drug Des Devel Ther; 2017; 11():2493-2505. PubMed ID: 28894357
[TBL] [Abstract][Full Text] [Related]
23. Demystifying Buprenorphine with Current Evidence-Based Practice in Acute and Chronic Pain Management.
Giron SE; Lai G; Griffis CA; Zhang SJ
AANA J; 2022 Jun; 90(3):225-233. PubMed ID: 35604865
[TBL] [Abstract][Full Text] [Related]
24. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
[TBL] [Abstract][Full Text] [Related]
25. Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain.
Pergolizzi JV; Raffa RB
J Pain Res; 2019; 12():3299-3317. PubMed ID: 31997882
[TBL] [Abstract][Full Text] [Related]
26. The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder.
De Aquino JP; Parida S; Sofuoglu M
Clin Drug Investig; 2021 May; 41(5):425-436. PubMed ID: 33818748
[TBL] [Abstract][Full Text] [Related]
27. Switching from high doses of pure μ-opioid agonists to transdermal buprenorphine in patients with cancer: a feasibility study.
Lundorff L; Sjøgren P; Hansen OB; Jonsson T; Nielsen PR; Christrup L
J Opioid Manag; 2013; 9(4):255-62. PubMed ID: 24353018
[TBL] [Abstract][Full Text] [Related]
28. An Examination of the Complex Pharmacological Properties of the Non-Selective Opioid Modulator Buprenorphine.
Pande LJ; Arnet RE; Piper BJ
Pharmaceuticals (Basel); 2023 Oct; 16(10):. PubMed ID: 37895868
[TBL] [Abstract][Full Text] [Related]
29. Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option.
Davis MP; Pasternak G; Behm B
Drugs; 2018 Aug; 78(12):1211-1228. PubMed ID: 30051169
[TBL] [Abstract][Full Text] [Related]
30. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus.
Pergolizzi JV; Mercadante S; Echaburu AV; Van den Eynden B; Fragoso RM; Mordarski S; Lybaert W; Beniak J; Orońska A; Slama O;
Curr Med Res Opin; 2009 Jun; 25(6):1517-28. PubMed ID: 19435402
[TBL] [Abstract][Full Text] [Related]
31. Benefit-Risk Analysis of Buprenorphine for Pain Management.
Hale M; Garofoli M; Raffa RB
J Pain Res; 2021; 14():1359-1369. PubMed ID: 34079354
[TBL] [Abstract][Full Text] [Related]
32. Buprenorphine for Pain: A Narrative Review and Practical Applications.
Spinella S; McCarthy R
Am J Med; 2024 May; 137(5):406-413. PubMed ID: 38340973
[TBL] [Abstract][Full Text] [Related]
33. Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review.
Spreen LA; Dittmar EN; Quirk KC; Smith MA
Pharmacotherapy; 2022 May; 42(5):411-427. PubMed ID: 35302671
[TBL] [Abstract][Full Text] [Related]
34. Pain Management in Patients With Opioid Use Disorder on Extended-release Buprenorphine: A Case Report.
South AM; Oller D; Lofwall M; Fanucchi LC
J Addict Med; 2024 Jan-Feb 01; 18(1):86-89. PubMed ID: 38039082
[TBL] [Abstract][Full Text] [Related]
35. Considerations and limitations of buprenorphine prescribing for opioid use disorder in the intensive care unit setting: A narrative review.
Erstad BL; Glenn MJ
Am J Health Syst Pharm; 2024 Mar; 81(6):171-182. PubMed ID: 37979138
[TBL] [Abstract][Full Text] [Related]
36. Transdermal buprenorphine in the treatment of chronic pain.
Sittl R
Expert Rev Neurother; 2005 May; 5(3):315-23. PubMed ID: 15938664
[TBL] [Abstract][Full Text] [Related]
37. Opioid agonist-antagonist drugs in acute and chronic pain states.
Hoskin PJ; Hanks GW
Drugs; 1991 Mar; 41(3):326-44. PubMed ID: 1711441
[TBL] [Abstract][Full Text] [Related]
38. Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations.
Coe MA; Lofwall MR; Walsh SL
J Addict Med; 2019; 13(2):93-103. PubMed ID: 30531584
[TBL] [Abstract][Full Text] [Related]
39. Inpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical Trial.
Seval N; Nunez J; Roth P; Schade M; Strong M; Frank CA; Litwin AH; Levin FR; Brady KT; Nunes EV; Springer SA
J Addict Med; 2023 Jul-Aug 01; 17(4):e232-e239. PubMed ID: 37579095
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
